Evidence map›Paper›PMID 38528290›Full record

ReviewInternational urology and nephrology2024

Apparent differences in prostate zones: susceptibility to prostate cancer, benign prostatic hyperplasia and prostatitis.

Xu-Dong Yu, Shao-Shuai Yan, Rui-Jia Liu, Yao-Sheng Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xu-Dong Yu *Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Shao-Shuai Yan *Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Rui-Jia Liu *Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yao-Sheng ZhangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. zhangyaosheng@bucm.edu.cn.ORCID http://orcid.org/0000-0002-9340-3479
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNBeijing Chang'an Integrated Traditional Chinese and Western Medicine Hospital · CNIntegrated Chinese Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Men are inevitably plagued by prostate disease throughout their lives. However, the understanding of the pathogenesis of prostate diseases is still limited. In the 1960s, McNeal proposed the theory of prostate zones: the prostate was divided into three main zones: transition zone, central zone, and peripheral zone. Over the past 50 years, significant differences between different prostate zones have been gradually revealed. We summarized the most significant differences in different zones of the prostate. For the first time, we proposed the "apparent difference in prostate zones" concept. This new concept has been proposed to understand the different zones of the prostate better. It also provided new ideas for exploring the susceptibility of lesions in different prostate zones. Despite the reported differences between zones, the treatment of prostate-related diseases remains partition agnostic. Therefore, we also discussed the clinical significance of the "apparent difference in the prostate zone" and emphasized the necessity of prostate zones.

Indexed as

ProstateProstatic HyperplasiaProstatic NeoplasmsProstatitisDisease SusceptibilityHumansMaleApparent differencesCentral zonePeripheral zoneProstateTransition zone

Identifiers

PMID38528290
OpenAlexW4393164105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.